- Home
- BMBL vs RIGL Comparison
BMBL vs RIGL Comparison
Compare BMBL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMBL | RIGL |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.9M | 911.8M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BMBL | RIGL |
|---|---|---|
| Price | $6.00 | $41.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $4.21 | ★ $59.25 |
| AVG Volume (30 Days) | ★ 11.7M | 215.7K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.97 |
| Revenue | ★ $965,658,000.00 | $294,282,000.00 |
| Revenue This Year | N/A | $3.77 |
| Revenue Next Year | N/A | $19.69 |
| P/E Ratio | ★ N/A | $20.18 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $2.44 | $24.84 |
| 52 Week High | $6.00 | $52.61 |
Technical Indicators
Market Signals| Indicator | BMBL | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 87.42 | 36.36 |
| Support Level | $2.62 | $33.93 |
| Resistance Level | $6.00 | $43.74 |
| Average True Range (ATR) | 0.03 | 2.37 |
| MACD | -0.10 | -1.02 |
| Stochastic Oscillator | 92.86 | 27.79 |
Price Performance
Historical ComparisonAbout BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.